VRTX

Vertex Pharmaceuticals
D

VRTX

451.24
USD
3.26
(0.73%)
مغلق
حجم التداول
0
الربح لكل سهم
0
العائد الربحي
-
P/E
-228
حجم السوق
116,466,038,082
الأفكار والتحليلات
    هشام منسي
    هشام منسي
    منذ شهرين
    buy
    VRTX
    VRTX
    2024-08-22 10:31
    VRTX Chart
    المزيد
أصول ذات صلة
    AMGN
    AMGN
    -12.22
    (-4.13%)
    287.81 USD
    BIIB
    BIIB
    -4.840
    (-2.94%)
    160.000 USD
    B
    BMRN
    -2.200
    (-3.35%)
    63.440 USD
    E
    EXEL
    -0.600
    (-1.71%)
    34.450 USD
    GILD
    GILD
    -3.715
    (-4.03%)
    88.385 USD
    I
    INCY
    -1.840
    (-2.37%)
    75.890 USD
    I
    IONS
    -2.970
    (-7.97%)
    34.290 USD
    REGN
    REGN
    -25.40
    (-3.25%)
    756.82 USD
    المزيد
الأخبار

العنوان: Vertex Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.